Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika Hamilton
Join the Oncology Brothers podcast as they dive into the highlights from ASCO 2024 with special guest Dr. Erika Hamilton, a breast medical oncologist from the Sarah Cannon Research Institute. In this episode, they discuss key abstracts in the world of breast cancer, including updates on RxPonder, PostMonarch, INAVO120, DESTINY-Breast06, and the Emerald Trial. Dr. Hamilton provides valuable insights on biomarker testing, CDK4/6 inhibitors, and groundbreaking advancements in HER2-targeted therapies. Discover how these studies are shaping treatment strategies for hormone receptor positive, HER2-low, and HER2-positive breast cancer patients. Don't miss out on this informative discussion packed with practical insights for community oncologists. Stay tuned for more ASCO 2024 highlights from the Oncology Brothers podcast. Website: http://www.oncbrothers.com/ Twitter: / oncbrothers Contact us at [email protected]
Medical advances in metastatic breast cancer treatment
How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care
Highlights From the 2026 ASCO GU Cancers Symposium
The Truth About Estrogen, Breast Cancer and Hormones with Dr Deb Matthew
Can a keto diet eliminate cancer growth? Dr. Thomas Seyfried says yes
#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024
HER2-Positive Metastatic Breast Cancer: Treatment Insights & Protocols w/ Dr. Hamilton | Ep. 48
Updates in Systemic Therapy for Breast Cancer 2/8/23
From Advanced to Early Breast Cancer: CDK4/6i Overview
Hormone Replacement After Breast Cancer? What Every Woman Deserves to Know
3 Breast Cancer Trials That Will Change Care in 2026
HR+ Breast Cancer Management - OncBrothers (Rohit & Rahul Gosain) w/ Dr. Margaret Gatti-Mays
Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast Cancer
ASCO2022 DESTINY BREAST 04 - How can we interpret a trial without pre or post treatment information?
ASCO 2024 and ESMO GI 2024 Updates Webinar | Feat. Dr. Samuel Klempner
SABCS 2023: Treatment Post CDK 4/6 Inhibitors
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer
The Functional Medicine Approach To Cancer and Cancer Recurrence
Breast Cancer Breakthroughs Episode 5: Moving the Needle for HER2-positive Breast Cancer
